Stephen Liu, Chief, Division of Hematology and Oncology at Georgetown Lombardi Comprehensive Cancer Center, shared on X:
“DCLung 26 advances in fusion positive NSCLC highlighted by Drs. Alfredo Addeo, Jessica J. Lin, Cristina Merkhofer and Alexander Drilon.
Exciting novel agents and greater understanding of resistance are pushing outcomes even higher.”
You might be interested in:
AMAZE-lung Trial: Triple Targeting With Amivantamab, Lazertinib and Bevacizumab in EGFR-Mutant NSCLC
